A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)

Anna Kalff; Jake Shortt; Flora Yuen; John Reynolds; Hang Quach; Craig Wallington-Beddoe; Patricia Walker; Simon Harrison; Dunn Rosanne; Andrew Spencer

doi:10.1097/01.HS9.0000563808.41508.98

A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)

Anna Kalff, Jake Shortt, Flora Yuen, John Reynolds, Hang Quach, Craig Wallington-Beddoe, Patricia Walker, Simon Harrison, Dunn Rosanne, Andrew Spencer

College of Medicine and Public Health

Research output: Contribution to journal › Meeting Abstract › peer-review

Abstract

Background:KappaMab is a chimeric IgG1 monoclonal antibody specific for Kappa Myeloma antigen (KMA), a tumour specific cell antigen exclusively expressed on the surface of kappa restricted MM cells. Early safety and efficacy signals seen with single-agent treatment in phase I/II studies in conjunction with observations that IMiD ® -treatment upregulates the KMA target and enhances effector cell cytotoxicity, provide rationale for this proof-of principal immune-oncology (IO) approach in a minimally pre-treated MM population.

Original language	English
Article number	PS1382
Pages (from-to)	633-634
Number of pages	2
Journal	HemaSphere
Volume	3
Issue number	S1
DOIs	https://doi.org/10.1097/01.HS9.0000563808.41508.98
Publication status	Published - Jun 2019
Event	24th Congress of the European Hematology Association - Amsterdam, Netherlands Duration: 13 Jun 2019 → 16 Jun 2019 Conference number: 24

Keywords

dexamethasone
lenalidomide
multiple myeloma
Antigens
hematotoxicity
thalidomide
abdominal pain
Kappa
Kappa Myeloma antigen (KMA)

Access to Document

10.1097/01.HS9.0000563808.41508.98Licence: In Copyright

Cite this

Kalff, A., Shortt, J., Yuen, F., Reynolds, J., Quach, H., Wallington-Beddoe, C., Walker, P., Harrison, S., Rosanne, D., & Spencer, A. (2019). A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16). HemaSphere, 3(S1), 633-634. Article PS1382. https://doi.org/10.1097/01.HS9.0000563808.41508.98

@article{ef87b0c584364e60b3c1f2aece60cc41,

title = "A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)",

abstract = "Background:KappaMab is a chimeric IgG1 monoclonal antibody specific for Kappa Myeloma antigen (KMA), a tumour specific cell antigen exclusively expressed on the surface of kappa restricted MM cells. Early safety and efficacy signals seen with single-agent treatment in phase I/II studies in conjunction with observations that IMiD {\textregistered} -treatment upregulates the KMA target and enhances effector cell cytotoxicity, provide rationale for this proof-of principal immune-oncology (IO) approach in a minimally pre-treated MM population.",

keywords = "dexamethasone, lenalidomide, multiple myeloma, Antigens, hematotoxicity, thalidomide, abdominal pain, Kappa, Kappa Myeloma antigen (KMA)",

author = "Anna Kalff and Jake Shortt and Flora Yuen and John Reynolds and Hang Quach and Craig Wallington-Beddoe and Patricia Walker and Simon Harrison and Dunn Rosanne and Andrew Spencer",

year = "2019",

month = jun,

doi = "10.1097/01.HS9.0000563808.41508.98",

language = "English",

volume = "3",

pages = "633--634",

journal = "HemaSphere",

issn = "2572-9241",

publisher = "Wolters Kluwer Health",

number = "S1",

note = "24th Congress of the European Hematology Association, EHA24 ; Conference date: 13-06-2019 Through 16-06-2019",

}

Kalff, A, Shortt, J, Yuen, F, Reynolds, J, Quach, H, Wallington-Beddoe, C, Walker, P, Harrison, S, Rosanne, D & Spencer, A 2019, 'A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)', HemaSphere, vol. 3, no. S1, PS1382, pp. 633-634. https://doi.org/10.1097/01.HS9.0000563808.41508.98

TY - JOUR

T1 - A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)

AU - Kalff, Anna

AU - Shortt, Jake

AU - Yuen, Flora

AU - Reynolds, John

AU - Quach, Hang

AU - Wallington-Beddoe, Craig

AU - Walker, Patricia

AU - Harrison, Simon

AU - Rosanne, Dunn

AU - Spencer, Andrew

N1 - Conference code: 24

PY - 2019/6

Y1 - 2019/6

N2 - Background:KappaMab is a chimeric IgG1 monoclonal antibody specific for Kappa Myeloma antigen (KMA), a tumour specific cell antigen exclusively expressed on the surface of kappa restricted MM cells. Early safety and efficacy signals seen with single-agent treatment in phase I/II studies in conjunction with observations that IMiD ® -treatment upregulates the KMA target and enhances effector cell cytotoxicity, provide rationale for this proof-of principal immune-oncology (IO) approach in a minimally pre-treated MM population.

AB - Background:KappaMab is a chimeric IgG1 monoclonal antibody specific for Kappa Myeloma antigen (KMA), a tumour specific cell antigen exclusively expressed on the surface of kappa restricted MM cells. Early safety and efficacy signals seen with single-agent treatment in phase I/II studies in conjunction with observations that IMiD ® -treatment upregulates the KMA target and enhances effector cell cytotoxicity, provide rationale for this proof-of principal immune-oncology (IO) approach in a minimally pre-treated MM population.

KW - dexamethasone

KW - lenalidomide

KW - multiple myeloma

KW - Antigens

KW - hematotoxicity

KW - thalidomide

KW - abdominal pain

KW - Kappa

KW - Kappa Myeloma antigen (KMA)

U2 - 10.1097/01.HS9.0000563808.41508.98

DO - 10.1097/01.HS9.0000563808.41508.98

M3 - Meeting Abstract

SN - 2572-9241

VL - 3

SP - 633

EP - 634

JO - HemaSphere

JF - HemaSphere

IS - S1

M1 - PS1382

T2 - 24th Congress of the European Hematology Association

Y2 - 13 June 2019 through 16 June 2019

ER -

A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)

Abstract

Keywords

Access to Document

Fingerprint

Cite this